Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Alzheimer disease (AD) is a neurodegenerative disorder characterized clinically by progressive memory loss and subsequent dementia and neuropathologically by senile plaques, neurofibrillary tangles, and synapse loss. Interestingly, a small percentage of individuals with normal antemortem psychometric scores meet the neuropathological criteria for AD (termed `preclinical' AD (PCAD)). In this study, inferior parietal lobule (IPL) from PCAD and control subjects were compared for oxidative stress markers by immunochemistry, amyloid beta-peptide by ELISA, and identification of protein expression differences by proteomics. We observed a significant increase in highly insoluble monomeric Aβ42, but no significant differences in oligomeric Aβ nor in oxidative stress measurements between controls and PCAD subjects. Expression proteomics identified proteins whose trends in PCAD are indicative of cellular protection, possibly correlating with previous studies showing no cell loss in PCAD. Our analyses may reveal processes involved in a period of protection from neurodegeneration that mimic the clinical phenotype of PCAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“Other conditions, such as frontotemporal degeneration and Pick's disease, among others, also contain tau-related deposits (Lee et al., 2001).”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 2×
“Because a growing body of evidence suggests that oxidative stress mediated by Aβ, possibly involving oligomerization of Aβ (Shankar et al., 2007; Walsh and Selkoe, 2007; Haass and Selkoe, 2007), is the propagator of cell death in AD (Butterfield et al., 2001; Markesbery, 1999), we sought to…”
BackgroundAmyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · cited 1×
“Senile plaques are mainly composed of amyloid beta peptide (Aβ), the latter produced via sequential cleavages of amyloid precursor protein (APP) by beta- and gamma-secretases (Haass et al., 1992; Shoji et al., 1992; Seubert et al., 1992).”
BackgroundIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · cited 1×
“Senile plaques are mainly composed of amyloid beta peptide (Aβ), the latter produced via sequential cleavages of amyloid precursor protein (APP) by beta- and gamma-secretases (Haass et al., 1992; Shoji et al., 1992; Seubert et al., 1992).”
BackgroundShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 2×
“Because a growing body of evidence suggests that oxidative stress mediated by Aβ, possibly involving oligomerization of Aβ (Shankar et al., 2007; Walsh and Selkoe, 2007; Haass and Selkoe, 2007), is the propagator of cell death in AD (Butterfield et al., 2001; Markesbery, 1999), we sought to…”
BackgroundProduction of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“Senile plaques are mainly composed of amyloid beta peptide (Aβ), the latter produced via sequential cleavages of amyloid precursor protein (APP) by beta- and gamma-secretases (Haass et al., 1992; Shoji et al., 1992; Seubert et al., 1992).”
BackgroundEvidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Self-citationNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 2×
“consensus report in 2009 from seven independent hospitals and aging centers, including the University of Kentucky, detailing this condition in cognitively normal aged individuals (Price et al., 2009).”
BackgroundResultSelf-citationAβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 1×
“This is a standard procedure in our laboratory, and details of the methodology and antibodies used are available (Das et al., 2003; McGowan et al., 2005;Murphy et al., 2007).”
MethodSelf-citation
Cited by
Sultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478
“However, studies from our laboratory showed proteomics changes in brain from subjects with PCAD [67], and in the transition from PCAD to amnestic MCI, including identification of carbonylated proteins that conceivably may be involved in memory loss of amnestic MCI compared to PCAD individuals [68].”
Self-citationLipid peroxidation and neurodegenerative disease
Reed, T. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.027 · Cited by 379
Tramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
Self-citationElevation of glutathione as a therapeutic strategy in Alzheimer disease
Pocernich, C. B., & Butterfield, D. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.003 · Cited by 346
Self-citationOxidative stress, protein modification and Alzheimer disease
Tramutola, A., Lanzillotta, C., Perluigi, M., & Butterfield, D. A. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.06.005 · Cited by 303
Self-citation
Metadata
- Authors
- Aluise, C. D., Robinson, R. A. S., Beckett, T. L., Murphy, M. P., Cai, J., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 39
- Issue
- 2
- Pages
- 221-228
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2164789180
- Cited by
- 83
- References
- 27
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics. https://app.cochat.ai/papers/10.1016/j.nbd.2010.04.011
- The paper
- Aluise, C. D., Robinson, R. A. S., Beckett, T. L., Murphy, M. P., Cai, J., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A. (2010). Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2010.04.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.